Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases. The company is dedicated to educating ...

Another company looking to initiate clinical trials with an epigenetic-editor-based treatment for hepatitis is nChroma Bio.

Durham-based Precision BioSciences Inc. has received investigational new drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for PBGENE-HBV, an in vivo gene editing program designed ...

Precision BioSciences (NASDAQ:DTIL – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued to clients and investors on ...

PBGENE-HBV specifically targets a highly conserved sequence within the hepatitis B viral genome. It utilises the ARCUS gene editing platform, delivering a nuclease-encoding mRNA to the liver ...

Chronic hepatitis B infection is primarily driven by persistence of HBV cccDNA and integration of HBV DNA into the human genome in liver ... cure chronic hepatitis B virus (HBV) infection.

HBV=hepatitis B virus. HBVDR=HBV drug resistance ... Due to the overlapping reading frames in the HBV genome, RAMs in reverse transcriptase can also lead to changes in the overlapping surface antigen ...

It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial ...

Earlier this month Scribe Therapeutics, a developer of CRISPR-based genome and epigenome editing ... a first-in-class treatment candidate for Hepatitis B (HBV) infection. Scribe has raised about ...

The genome-wide significant SNPs at the novel locus of ... Thus, the above evidence suggests that HMGB1 senses HBV/HCV virus infection and transduces that signal to the autophagy pathway and ...